ILEX Oncology

Based in San Antonio, Texas, ILEX has a marketed product, Campath®, a treatment for patients with refractory chronic lymphocytic leukemia. ILEX is also advancing a robust pipeline of oncology product candidates. The pipeline comprises multiple technologies at all stages of clinical development, including a monoclonal antibody, apoptosis-inducing agents, cytotoxic compounds with novel mechanisms of action, angiogenesis inhibitors and chemoprevention agents.

Contact Details: 11550 IH 10 West San Antonio TX 78230 United States of America Tel: Fax: Email: WWW: www.ilexonc.com/

Loading...

Recent Publications by ILEX Oncology:
Formal synthesis of angiogenesis inhibitor NM-3. We report the formal synthesis of angiogenesis inhibitor NM-3 (1) in six...	9th March, 2004	Department of Process Chemistry, Ilex Oncology, Inc., 14785 Omicron Drive,	J Org Chem. 2003 Jul 25;68(15):5967-73. DOI Direct Link
Expression of nuclear receptors and apo E secretion during the differentiation of monocytic THP-1 cells into macrophages. The human monocytic THP-1 cell line differentiates into macrophage-like...	6th January, 2004	ILEX Oncology Research, Geneva, Switzerland.	Cell Biol Toxicol. 2003 Apr;19(2):95-105.

Press Releases on ILEX Oncology:
Pharmacyclics, Inc. Announces Board and Management Transitions	11th September, 2008	Pharmacyclics, Inc.	SUNNYVALE, Calif., Sept. 11 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (the "Company" or "Pharmacyclics") announced today that Christine A. White, M.D., Richard M. Levy Ph.D
BioSeeker launches new report "The Global Structure of Prostate	1st January, 1970	Bioseeker	BioSeeker launches new report "The Global Structure of Prostate Cancer R&D" In Europe and the US there are close to 20 million

ILEX Oncology Clinical Trials:
Marimastat in Treating Patients With Stage III Non-Small Cell Lung Cancer

ILEX Oncology Patents:
US Patent No.	Title
6872711	.beta.-substituted .beta.-aminoethyl phosphonate derivatives
6602910	D-enantiomer of DFMO and methods of use therefor
6589981	Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives
6573290	DFMO and celecoxib in combination for cancer chemoprevention and therapy
6277411	Pharmaceutical formulation containing DFMO for the treatment of cancer
→View more ILEX Oncology patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 452 times since April 2007, the link to the organisation's website has been followed 80 times

Recent Search Terms used to find this page: ilex oncology dfmo | DFMO ILEX | .

Search for more companies in San Antonio

Search for more companies in TX

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for ILEX Oncology